Precigen (PGEN) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precigen (PGEN) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 127.8% versus a gain of 74.8%. Over five years, PGEN leads with a +62.2% price change compared with -28.7% for RCUS. Arcus Biosciences is the larger company by market cap ($3.08 billion vs $2.70 billion), about 1.1 times the size, while Precigen is growing revenue faster (+146.7% vs -4.3%).
Arcus Biosciences converts more of its revenue into profit, with a net margin of -142.9% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGEN | RCUS |
|---|---|---|
| Share price | $7.54 | $24.52 |
| Market cap | $2.70B | $3.08B |
| 1-day change | -0.13% | +0.99% |
| YTD return | +80.38% | +2.90% |
| 1-year return | +127.79% | +74.77% |
| 5-year return | +62.15% | -28.70% |
| EPS (TTM) | $-1.04 | $-3.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.68M | $247.00M |
| Revenue growth (YoY) | +146.73% | -4.26% |
| Net income (latest FY) | $-250.64M | $-353.00M |
| Operating margin | -1141.13% | -156.28% |
| Net margin | -2588.21% | -142.91% |
| 52-week high | $8.98 | $31.74 |
| 52-week low | $2.99 | $14.26 |
| Distance from 52-week high | -16.04% | -22.74% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +81.03% | +62.77% |
| Average volume | 5.03M | 1.32M |
| Shares outstanding | 358.04M | 125.77M |
| Employees | 160 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed RCUS by 53.0 percentage points over the past year.
- Arcus Biosciences is more profitable, keeping -142.9 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs -4.26%).
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
PGEN vs RCUS FAQ
Which is bigger, Precigen or Arcus Biosciences?
Arcus Biosciences (RCUS) is larger, with a market capitalization of $3.08B compared with $2.70B for Precigen (PGEN).
Which stock has performed better over the past year, PGEN or RCUS?
PGEN returned +127.79% over the past 12 months, compared with +74.77% for RCUS (price return, excluding dividends). Past performance does not predict future results.
Are Precigen and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.